Sol-Gel Technologies (SLGL) Operating Leases (2019 - 2026)
Sol-Gel Technologies (SLGL) reported Operating Leases of $377000.0 for Q1 2026, down 49.46% year-over-year from $746000.0 in Q1 2025, and down 23.99% quarter-over-quarter from $496000.0 in Q4 2025.
Sol-Gel Technologies (SLGL) Operating Leases (2019 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 8 years of Operating Leases data on file, last reported at $377000.0 in Q1 2026.
- Operating Leases for Q1 2026 came in at $377000.0, down 49.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $377000.0 (down 49.46% YoY), and the FY2025 annual result was $496000.0, down 43.51% from the prior year.
- Operating Leases retreated to $377000.0 in Q1 2026 per SLGL's latest filing, from $496000.0 in the prior quarter.
- Over five years, Operating Leases peaked at $1.2 million in Q3 2023 and troughed at $30000.0 in Q1 2023.
- A 5-year average of $627764.7 and a median of $600000.0 in 2022 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2024: Operating Leases sank 95.0% in 2023, then jumped 3676.67% in 2024.
- A 5-year view of Operating Leases shows it stood at $54000.0 in 2022, then surged by 2133.33% to $1.2 million in 2023, then slipped by 27.2% to $878000.0 in 2024, then sank by 43.51% to $496000.0 in 2025, then dropped by 23.99% to $377000.0 in 2026.
- Business Quant data shows SLGL's Operating Leases at $377000.0 in Q1 2026, $496000.0 in Q4 2025, and $592000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 377,000.00 |
| Dec 31, 2025 | 496,000.00 |
| Sep 30, 2025 | 592,000.00 |
| Jun 30, 2025 | 700,000.00 |
| Mar 31, 2025 | 746,000.00 |
| Dec 31, 2024 | 878,000.00 |
| Sep 30, 2024 | 922,000.00 |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | 1.13 Mn |
| Dec 31, 2023 | 1.21 Mn |
| Sep 30, 2023 | 1.22 Mn |
| Jun 30, 2023 | 136,000.00 |
| Mar 31, 2023 | 30,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Sep 30, 2022 | 193,000.00 |
| Jun 30, 2022 | 369,000.00 |
| Mar 31, 2022 | 600,000.00 |
| Dec 31, 2021 | 810,000.00 |
| Sep 30, 2021 | 803,000.00 |
| Jun 30, 2021 | 958,000.00 |